Filing Flows

Filing Flows › 8-K events › Lunai Bioworks

Lunai Bioworks: departure or appointment of directors and officers

Form 8-K filed Oct 23, 2026 · items 3.01, 5.02, 7.01, 8.01

Delisting noticesLunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

What the filing says

On October 22, 2026, Nathen Fuentes resigned as Chief Financial Officer of the Company, effective immediately. Fuentes stated that his decision was not the result of any disagreement regarding accounting principles or financial statement disclosures.

Read the filing on SEC EDGAR →

What usually followsAcross 492 8-Ks reporting Item 3.01 (delisting notice or listing-rule failure) in our universe, the stock's median move the next session was 0.0% (typical size ±2.1%, up 46% of the time); over the following 21 sessions, −0.2%. Item 5.02: −0.1% next session across 39,174. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 3.01 — Notice of delisting or failure to meet a listing standard. A delisting notice starts a compliance window; companies often answer with a reverse split, a plan, or a move to another market.

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Lunai Bioworks at a glance

Latest quarterQ4 FY26
Revenue$31K
Operating marginn/m
IndustryPharmaceutical Preparations

Lunai Bioworks, Q4 FY26: revenue $31K. The chart follows the revenue to costs, profit and cash.

Lunai Bioworks: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent delisting notices

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.